新治疗前沿:CD19靶向CAR-T细胞疗法在类风湿关节炎中的应用
该文基于一例血清阳性RA重叠SSc患者接受CD19 CAR-T细胞(KYV-101)治疗后12个月持续缓解并间质性肺病改善的案例,结合文献复习已发表的8例RA接受CAR-T治疗病例,发现多数患者停用免疫抑制治疗后病情稳定,仅1例出现高级别细胞因子释放综合征和神经毒性,提示CAR-T在难治性RA中具有潜力但需更大前瞻性研究。
要点
- 8例已报告RA病例中7例ACPA阳性,多数停用免疫抑制治疗后中位随访9个月病情稳定。
- 仅1例出现3级细胞因子释放综合征和4级免疫细胞相关神经毒性综合征,2例出现短暂低丙种球蛋白血症。
- 未观察到严重感染,提示CD19 CAR-T在难治性RA中安全性可控但需长期验证。
核心结论
- 8例报告病例提示CD19 CAR-T细胞疗法对难治性RA(包括对B细胞靶向治疗无应答者)具有潜在疗效。
研究设计与样本
- 本文报告1例血清阳性RA重叠SSc患者接受单次自体CD19 CAR-T细胞(KYV-101)输注(氟达拉滨和环磷酰胺清淋后),监测12个月临床、血清学及安全性结局,并进行文献复习分析既往RA接受CAR-T治疗的病例。
主要发现
- 本例患者12个月内持续疾病缓解且间质性肺病改善。
- 已发表8例RA接受CAR-T治疗中7例ACPA阳性,多数患者在中位随访9个月时停用免疫抑制治疗且病情稳定。
- 仅1例报告3级细胞因子释放综合征和4级免疫细胞相关神经毒性综合征。
- 2例(2/8)出现短暂低丙种球蛋白血症,未观察到严重感染。
关键数值与推荐
- 8例中7例(7/8)ACPA阳性;中位随访9个月;2例(2/8)出现短暂低丙种球蛋白血症。
临床怎么用
- CD19 CAR-T细胞疗法可考虑作为难治性RA(尤其对B细胞靶向治疗无应答者)的潜在新选择,但需在严密监测下进行并关注细胞因子释放综合征、神经毒性及低丙种球蛋白血症。
局限性
- 证据基于8例已报告病例(含本例),样本量小且为回顾性文献复习,需更大规模前瞻性研究评估长期疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Chimeric antigen receptor (CAR)-T cell therapy recently emerged as a possible new treatment option in refractory systemic autoimmune diseases (AID). With growing evidence in B cell-mediated AID, the question arises as to its potential application in difficult to treat RA. Building on positive experience in a case of overlapping seropositive RA and SSc treated with CD19 CAR-T cells at our centre, we reviewed the available evidence on the efficacy and safety of CAR-T cell therapy in RA. METHODS: The patient successfully received a single infusion of autologous CD19 CAR-T cells (KYV-101, Kyverna Therapeutics) after lymphodepletion with fludarabine and CYC. Clinical, serologic and safety outcomes were monitored over 12 months, demonstrating sustained disease remission and improvement in interstitial lung disease. Furthermore, a literature review analysed prior cases of CAR-T cell treatment in RA, focusing on patient characteristics, outcomes and adverse events. RESULTS: Seven of eight previously published cases of CAR-T cell therapy in RA (7/8 ACPA positive) consistently reported significant improvement, with most patients remained stable off immunosuppressive therapy after a median follow-up of 9 months. High-grade cytokine release syndrome (grade 3) and immune cell-associated neurotoxicity syndrome (grade 4) was reported only in one patient. No serious infections were observed, even though transient hypogammoglobulinaemia occurred in two patients (2/8). CONCLUSION: The eight reported cases highlight the potential of CAR-T cell therapy, even in patients unresponsive to B cell-targeted treatments in RA. Larger and prospective studies are needed to assess its long-term efficacy and safety in the disease.
引用
- Kremer P, Haase I, Richter J, et al. A new therapeutic frontier: CD19-targeting CAR-T cell therapy in rheumatoid arthritis: a concise report. Rheumatology (Oxford). 2026. PMID: 41984818. doi:10.1093/rheumatology/keag195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。